{"denoms":[{"counts":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"271"}],"units":"Participants"}],"groups":[{"description":"Participants received obinutuzumab, 1000 mg as an IV infusion on Day 1 and Weeks 2, 24, 26, and either Weeks 50 and 52 or Week 52 only, along with MMF and SOC therapy. Placebo was administered at Week 50 for participants not treated with obinutuzumab. Participants with adequate response at Week 76 continued to receive obinutuzumab at Week 80 and Q6M thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"BG000","title":"Obinutuzumab"},{"description":"Participants received Obinutuzumab matching placebo as an IV infusion on Day 1 and Weeks 2, 24, 26, 50, and 52. Participants also received SOC therapy and MMF. Participants with adequate response at Week 76 continued to receive placebo at Week 80 and Q6M thereafter.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.5","value":"33.0"},{"groupId":"BG001","spread":"10.0","value":"32.7"},{"groupId":"BG002","spread":"10.2","value":"32.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"229"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"42"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"156"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"102"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"51"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"129"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"20"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, demographic and baseline characteristics were to be provided for obinutuzumab (combined treatment groups) and placebo groups."}